In previous studies, EGFR C797S mutation was identified as the main molecular alteration associated with the first-line treatment failure of osimertinib, occurring in 9.5% (2/21),21 11.1% (3/27),22 and 19.6% (9/46)23 of patients by tumor tissue detection. Here, EGFR is linked to neoplasm.